| scholarly article | Q13442814 |
| P2093 | author name string | Surendra S Katyare | |
| Mahabaleshwar V Hegde | |||
| Deepak M Kasote | |||
| P2860 | cites work | Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease | Q37557789 |
| Role of Protein Aggregation in Mitochondrial Dysfunction and Neurodegeneration in Alzheimer's and Parkinson's Diseases | Q22241397 | ||
| Mitochondrial modulators for bipolar disorder: A pathophysiologically informed paradigm for new drug development | Q22241837 | ||
| Localization of glucocorticoid hormone receptors in mitochondria of human cells | Q22254577 | ||
| Ca2+-dependent mechanisms of presynaptic control at central synapses | Q22337008 | ||
| Estrogenic control of mitochondrial function and biogenesis | Q24651145 | ||
| Alpha-lipoic acid as a biological antioxidant | Q27863439 | ||
| Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer's disease neurons: implications for mitochondrial dysfunction and neuronal damage | Q28114981 | ||
| Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools | Q28241521 | ||
| Mitochondria: dynamic organelles in disease, aging, and development | Q28249783 | ||
| Oxidative stress in psychiatric disorders: evidence base and therapeutic implications | Q28265319 | ||
| Supplementation of vitamin C with atypical antipsychotics reduces oxidative stress and improves the outcome of schizophrenia | Q28269799 | ||
| Huntington's disease | Q28284355 | ||
| Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases | Q28300234 | ||
| Structural and functional alterations in mitochondrial membrane in picrotoxin-induced epileptic rat brain | Q28571815 | ||
| Effect of experimental thyrotoxicosis on oxidative phosphorylation in rat liver, kidney and brain mitochondria | Q28578529 | ||
| Nitric oxide reacts with intracellular glutathione and activates the hexose monophosphate shunt in human neutrophils: evidence for S-nitrosoglutathione as a bioactive intermediary | Q28611729 | ||
| Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease | Q28748304 | ||
| Impaired balance of mitochondrial fission and fusion in Alzheimer's disease | Q28854335 | ||
| Mitochondrial membrane permeabilization in cell death | Q29547425 | ||
| Mitochondrial dynamics--fusion, fission, movement, and mitophagy--in neurodegenerative diseases | Q29615646 | ||
| Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. | Q30440422 | ||
| Origin and functional consequences of the complex I defect in Parkinson's disease | Q30469425 | ||
| Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia | Q33179595 | ||
| Neuroanatomical pattern of mitochondrial complex I pathology varies between schizophrenia, bipolar disorder and major depression | Q33383204 | ||
| A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease | Q33693140 | ||
| Alpha-synuclein in Lewy body disease and Alzheimer's disease | Q33750063 | ||
| Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington's disease, Alzheimer's disease and parkinsonism | Q33834203 | ||
| Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases | Q33837238 | ||
| Creatine and its potential therapeutic value for targeting cellular energy impairment in neurodegenerative diseases | Q33917550 | ||
| N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington's disease | Q45306350 | ||
| Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients | Q46203164 | ||
| Quinone and oxyradical scavenging properties of N-acetylcysteine prevent dopamine mediated inhibition of Na+, K+-ATPase and mitochondrial electron transport chain activity in rat brain: implications in the neuroprotective therapy of Parkinson's dise | Q46527836 | ||
| Influence of thyroid hormone treatment on the respiratory activity of cerebral mitochondria from hypothyroid rats. A critical re-assessment | Q46591618 | ||
| Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice | Q46737335 | ||
| Mitochondrial damage induced by fetal hyperphenylalaninemia in the rat brain and liver: its prevention by melatonin, Vitamin E, and Vitamin C. | Q46821816 | ||
| Ageing-induced alterations in lipid/phospholipid profiles of rat brain and liver mitochondria: implications for mitochondrial energy-linked functions | Q46837792 | ||
| Effect of alloxan-diabetes and subsequent treatment with insulin on lipid/phospholipid composition of rat brain microsomes and mitochondria | Q46948763 | ||
| Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease | Q48216036 | ||
| Genetic and functional abnormalities of the melatonin biosynthesis pathway in patients with bipolar disorder | Q48238820 | ||
| Effect of thyroid deficiency on oxidative phosphorylation in rat liver, kidney, and brain mitochondria | Q48280876 | ||
| Effects of glucocorticoids on oxidative stress-induced hippocampal cell death: implications for the pathogenesis of Alzheimer's disease | Q48288003 | ||
| Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease | Q48404181 | ||
| Brain Cytochrome Oxidase in Alzheimer's Disease | Q48453334 | ||
| Mitochondria: mitochondrial membranes in brain ageing and neurodegeneration | Q48457687 | ||
| Mitochondrial membrane fluidity and oxidative damage to mitochondrial DNA in aged and AD human brain | Q48710279 | ||
| A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study | Q48725577 | ||
| Disorders from perturbations of nuclear-mitochondrial intergenomic cross-talk. | Q50303408 | ||
| Expression analyses of the mitochondrial complex I 75-kDa subunit in early onset schizophrenia and autism spectrum disorder: increased levels as a potential biomarker for early onset schizophrenia | Q50306114 | ||
| Mitochondrial transcription factor A overexpression and base excision repair deficiency in the inner ear of rats with D-galactose-induced aging | Q50433955 | ||
| Reduced Activities of Thiamine-Dependent Enzymes in the Brains and Peripheral Tissues of Patients With Alzheimer's Disease | Q53192901 | ||
| Effect of aluminium-induced Alzheimer like condition on oxidative energy metabolism in rat liver, brain and heart mitochondria. | Q53232811 | ||
| Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)? | Q53264266 | ||
| Effect of vitamin E administration on the elevated oxygen stress and the telomeric and subtelomeric status in Alzheimer's disease. | Q53322100 | ||
| Oxidative stress and heart failure in altered thyroid States | Q58915024 | ||
| Mitochondrial mechanisms of estrogen neuroprotection | Q33927797 | ||
| beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease | Q33947152 | ||
| Glutathione, oxidative stress and neurodegeneration | Q33994473 | ||
| Melatonin as a potential therapeutic agent in psychiatric illness. | Q34018192 | ||
| Mitochondrial dysfunction and intracellular calcium dysregulation in ALS | Q34103782 | ||
| Age-related structural and functional changes of brain mitochondria. | Q34104048 | ||
| Mitochondrial complex I activity and oxidative damage to mitochondrial proteins in the prefrontal cortex of patients with bipolar disorder | Q34108449 | ||
| Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia | Q34137363 | ||
| Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease | Q34163054 | ||
| N-acetyl cysteine restores brain glutathione loss in combined 2-cyclohexene-1-one and d-amphetamine-treated rats: relevance to schizophrenia and bipolar disorder | Q34188115 | ||
| DJ-1 null dopaminergic neuronal cells exhibit defects in mitochondrial function and structure: involvement of mitochondrial complex I assembly | Q34189590 | ||
| Glucocorticoid receptor 1B and 1C mRNA transcript alterations in schizophrenia and bipolar disorder, and their possible regulation by GR gene variants. | Q34199632 | ||
| Therapeutic prospects for mitochondrial disease | Q34205124 | ||
| Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses | Q34230044 | ||
| Deceleration of fusion-fission cycles improves mitochondrial quality control during aging | Q34325475 | ||
| Glucocorticoid receptor mRNA and protein isoform alterations in the orbitofrontal cortex in schizophrenia and bipolar disorder | Q34343734 | ||
| The other, forgotten genome: mitochondrial DNA and mental disorders | Q34416941 | ||
| Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury | Q34561378 | ||
| Brain bioenergetics and response to triiodothyronine augmentation in major depressive disorder | Q34587328 | ||
| Mitochondrial dysfunction and molecular pathways of disease | Q34604563 | ||
| Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage | Q34627072 | ||
| Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity | Q34634421 | ||
| Assessing mitochondrial dysfunction in cells. | Q34793639 | ||
| Vitamin E therapy in Parkinson's disease | Q35160394 | ||
| Activation of the mitochondrial permeability transition pore modulates Ca2+ responses to physiological stimuli in adult neurons | Q35245867 | ||
| Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease | Q35579334 | ||
| Mitochondrial fission in apoptosis, neurodegeneration and aging | Q35595919 | ||
| Mitochondrial medicine for aging and neurodegenerative diseases | Q35606693 | ||
| Mitochondrial energetics and therapeutics | Q35632864 | ||
| Mitochondrial DNA deletions and differential mitochondrial DNA content in Rhesus monkeys: implications for aging | Q35645470 | ||
| Impaired mitochondrial biogenesis contributes to mitochondrial dysfunction in Alzheimer's disease | Q35660223 | ||
| Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: implications to mitochondria-targeted antioxidant therapeutics | Q35737647 | ||
| Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease | Q35747131 | ||
| Evidence for behavioral benefits of early dietary supplementation with CoEnzymeQ10 in a slowly progressing mouse model of Huntington's disease | Q35754248 | ||
| Abnormal mitochondrial dynamics and neurodegenerative diseases | Q37607449 | ||
| Parkinson's disease and mitochondrial complex I: a perspective on the Ndi1 therapy | Q37630973 | ||
| Mitochondria-targeted antioxidant peptides. | Q37778084 | ||
| Nitrosylation and nitration of mitochondrial complex I in Parkinson's disease. | Q37785104 | ||
| Mitochondrial quality control and Parkinson's disease: a pathway unfolds | Q37814216 | ||
| Parkinson's syndrome and Parkinson's disease in mitochondrial disorders | Q37850755 | ||
| Mitochondrial calcium homeostasis as potential target for mitochondrial medicine | Q37907474 | ||
| Elevation of glutathione as a therapeutic strategy in Alzheimer disease | Q37947939 | ||
| Parkin, PINK1 and mitochondrial integrity: emerging concepts of mitochondrial dysfunction in Parkinson's disease | Q37953288 | ||
| Estrogen and the regulation of mitochondrial structure and function in the brain | Q37983332 | ||
| Melatonin: an overlooked factor in schizophrenia and in the inhibition of anti-psychotic side effects | Q38004964 | ||
| Mitochondria as sources and targets of damage in cellular aging | Q38032465 | ||
| Novel S-acyl glutathione derivatives prevent amyloid oxidative stress and cholinergic dysfunction in Alzheimer disease models | Q39397930 | ||
| PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease. | Q39476389 | ||
| Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia | Q39577276 | ||
| Melatonin treatment restores mitochondrial function in Alzheimer's mice: a mitochondrial protective role of melatonin membrane receptor signaling | Q39585259 | ||
| In vitro and in vivo neuroprotection by gamma-glutamylcysteine ethyl ester against MPTP: relevance to the role of glutathione in Parkinson's disease. | Q40286709 | ||
| Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression | Q40301497 | ||
| Mitochondria-targeted peptide prevents mitochondrial depolarization and apoptosis induced by tert-butyl hydroperoxide in neuronal cell lines | Q40363556 | ||
| Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release | Q40551652 | ||
| Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia | Q40577513 | ||
| Superoxide production by the mitochondrial respiratory chain | Q41488866 | ||
| Glucagon stimulates ketone utilization by rat brain slices | Q41571757 | ||
| Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease | Q41945324 | ||
| Bcl-2 SNP rs956572 associates with disrupted intracellular calcium homeostasis in bipolar I disorder | Q42483967 | ||
| Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia | Q42501952 | ||
| New evidence for the involvement of mitochondrial inheritance in schizophrenia: results from a cross-sectional study evaluating the risk of illness in relatives of schizophrenia patients | Q42643074 | ||
| Is it time to reassess alpha lipoic acid and niacinamide therapy in schizophrenia? | Q42937883 | ||
| Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease | Q43468224 | ||
| Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity | Q43517278 | ||
| Localization of the glucocorticoid receptor in rat brain mitochondria. | Q43613409 | ||
| Influence of vitamin E and C supplementation on lipoprotein oxidation in patients with Alzheimer's disease | Q43680826 | ||
| Ethanol impairs insulin-stimulated mitochondrial function in cerebellar granule neurons | Q43839526 | ||
| State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia | Q44194149 | ||
| Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy | Q44214157 | ||
| Substrate-specific stimulation by glucagon of isolated murine brain mitochondrial oxidative phosphorylation | Q44440805 | ||
| Ascorbate treatment attenuates the Huntington behavioral phenotype in mice | Q44490151 | ||
| Coenzyme Q10 reduces beta-amyloid plaque in an APP/PS1 transgenic mouse model of Alzheimer's disease | Q44495822 | ||
| Effect of corticosterone treatment on mitochondrial oxidative energy metabolism in developing rat brain. | Q44574732 | ||
| Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients | Q44680500 | ||
| Cell cycle activation linked to neuronal cell death initiated by DNA damage | Q44774050 | ||
| Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease | Q45107385 | ||
| Mitochondrial defect in Huntington's disease caudate nucleus | Q45291734 | ||
| Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. | Q45293805 | ||
| Effect of coenzyme Q10 and vitamin E on brain energy metabolism in the animal model of Huntington's disease | Q45299091 | ||
| Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. | Q45302702 | ||
| Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain | Q45304576 | ||
| Mitochondria as a therapeutic target for aging and neurodegenerative diseases | Q35807409 | ||
| Delaying the mitochondrial decay of aging | Q35833024 | ||
| The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. | Q35908404 | ||
| Mitochondrial decay in hepatocytes from old rats: membrane potential declines, heterogeneity and oxidants increase | Q36077271 | ||
| Genetic inactivation of mitochondria-targeted redox enzyme p66ShcA preserves neuronal viability and mitochondrial integrity in response to oxidative challenges | Q36106275 | ||
| Progesterone and Cerebral Function during Emotion Processing in Men and Women with Schizophrenia | Q36169081 | ||
| Mitochondria and neurotransmission: evacuating the synapse | Q36213274 | ||
| Oxidative stress, α-tocopherol, ascorbic acid and reduced glutathione status in schizophrenics | Q36265242 | ||
| Identification of glucagon receptors in rat brain | Q36272209 | ||
| Melatonin and Parkinson's disease | Q36282830 | ||
| The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus | Q36352353 | ||
| Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease | Q36375845 | ||
| The neurological disorder associated with thyroid autoimmunity | Q36512186 | ||
| The role of mitochondria in inherited neurodegenerative diseases | Q36521932 | ||
| Targeting antioxidants to mitochondria by conjugation to lipophilic cations. | Q36609730 | ||
| A century of Alzheimer's disease | Q36643414 | ||
| Melatonin role in the mitochondrial function. | Q36664479 | ||
| Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders | Q36664537 | ||
| Mitochondrial dysfunction in human pathologies. | Q36664543 | ||
| Progesterone and estrogen regulate oxidative metabolism in brain mitochondria | Q36692052 | ||
| Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia | Q36739461 | ||
| The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview | Q36867029 | ||
| Role of mitochondrial DNA in calcium signaling abnormality in bipolar disorder. | Q37051703 | ||
| Dynamic regulation of mitochondrial function by glucocorticoids | Q37087119 | ||
| Parkinson's disease-associated DJ-1 mutations impair mitochondrial dynamics and cause mitochondrial dysfunction | Q37087927 | ||
| Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis | Q37120081 | ||
| The mitochondrial antioxidants MitoE(2) and MitoQ(10) increase mitochondrial Ca(2+) load upon cell stimulation by inhibiting Ca(2+) efflux from the organelle | Q37177530 | ||
| Glutathione: a novel treatment target in psychiatry | Q37185741 | ||
| Mitochondria in neuroplasticity and neurological disorders | Q37216404 | ||
| Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease | Q37321251 | ||
| Combined R-alpha-lipoic acid and acetyl-L-carnitine exerts efficient preventative effects in a cellular model of Parkinson's disease. | Q37334961 | ||
| Mitochondria: a therapeutic target in neurodegeneration | Q37466059 | ||
| Cause and consequence: mitochondrial dysfunction initiates and propagates neuronal dysfunction, neuronal death and behavioral abnormalities in age-associated neurodegenerative diseases. | Q37466088 | ||
| Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta | Q37555305 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 392-406 | |
| P577 | publication date | 2013-03-05 | |
| P1433 | published in | BioFactors | Q15767404 |
| P1476 | title | Mitochondrial dysfunction in psychiatric and neurological diseases: cause(s), consequence(s), and implications of antioxidant therapy | |
| P478 | volume | 39 |
| Q45843246 | A H2O2-Responsive Theranostic Probe for Endothelial Injury Imaging and Protection |
| Q39345969 | A critical review on hepatoprotective effects of bioactive food components. |
| Q64129644 | Active Components, Antioxidant, Inhibition on Metabolic Syndrome Related Enzymes, and Monthly Variations in Mature Leaf Hawk Tea |
| Q51193041 | Carnosic Acid Suppresses the H2O2-Induced Mitochondria-Related Bioenergetics Disturbances and Redox Impairment in SH-SY5Y Cells: Role for Nrf2. |
| Q47863411 | Carnosic Acid as a Promising Agent in Protecting Mitochondria of Brain Cells |
| Q38743021 | Epigenetic Treatment of Neuropsychiatric Disorders: Autism and Schizophrenia. |
| Q41858286 | Improvement of oxidative and metabolic parameters by cellfood administration in patients affected by neurodegenerative diseases on chelation treatment. |
| Q57136271 | Natural Phytotherapeutic Antioxidants in the Treatment of Mercury Intoxication-A Review |
| Q37661357 | Novel therapeutic targets in depression and anxiety: antioxidants as a candidate treatment |
| Q34094532 | Oxidative stress, mitochondrial damage and neurodegenerative diseases |
| Q46433045 | Pinocembrin Suppresses H2O2-Induced Mitochondrial Dysfunction by a Mechanism Dependent on the Nrf2/HO-1 Axis in SH-SY5Y Cells |
| Q43807948 | Protective effects of erythropoietin against cuprizone-induced oxidative stress and demyelination in the mouse corpus callosum |
| Q39173672 | Resveratrol and Brain Mitochondria: a Review |
| Q38544272 | Significance of antioxidant potential of plants and its relevance to therapeutic applications. |
| Q50878532 | Sulforaphane Promotes Mitochondrial Protection in SH-SY5Y Cells Exposed to Hydrogen Peroxide by an Nrf2-Dependent Mechanism. |
Search more.